The global mRNA vaccines and therapeutics market was valued at USD 65.27 Billion in 2025, driven by the rising incidence of chronic diseases and increasing awareness of the widespread potential of mRNA technology across the globe. The market is expected to grow at a CAGR of 1.20% during the forecast period of 2026-2035, with the values to reach USD 73.54 Billion by 2035.
Base Year
Historical Period
Forecast Period
In November 2023, Japan approved ARCT-154, the first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine globally. The vaccine is developed by CSL and Arcturus Therapeutics, registering a significant milestone in vaccine innovation.
In March 2024, Strand Therapeutics discovered an improved class of mRNA molecules, designed to detect types of encountered cells and target diseased cells.
The global prevalence of non-communicable diseases (NCDs) drives market growth for mRNA vaccines and therapeutics.
Compound Annual Growth Rate
1.2%
Value in USD Billion
2026-2035
*this image is indicative*
mRNA vaccines and therapeutics utilise messenger RNA molecules to instruct cells to produce proteins that trigger immune responses or treat diseases. The market is poised to be driven by rapid vaccine development, expanding applications of mRNA technology beyond infectious diseases, technological advancements enhancing efficacy and safety, increasing investments from public and private sectors, and regulatory support for innovative mRNA-based treatments. These factors collectively propel market growth, revolutionising healthcare with promising therapeutic innovations.
Prevalence of Chronic Diseases Aiding the Market Demand
The market is poised for substantial growth due to the rising prevalence of chronic diseases globally. As per the data released by the World Health Organization, non-communicable diseases NCD claims nearly 41 million people per year which is approximately equivalent to 74% of all deaths worldwide.
The most common medical conditions that are the common cause of high deaths include cardiovascular diseases accounting for most NCD deaths, or 17.9 million people each year, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).
The rapidly changing lifestyle habits among people including tobacco consumption, physical inactivity, excess alcohol intake, unhealthy diets, and air pollution are categorised as common risk factors of NCDs.
Surge in Research and Development Initiatives to Boost mRNA Vaccines and Therapeutics Market Demand
In March 2024, MIT spinout Strand Therapeutics made significant advancements in the field of mRNA technology by developing a new class of mRNA molecules. It is capable of sensing the type of cells they encounter in the body and expressing therapeutic proteins specifically in diseased cells.
The success of such research initiatives may contribute to a surge in targeted mRNA therapies, accelerating regulatory approvals and adoption in healthcare settings. The market is anticipated to experience significant expansion in the mRNA therapeutics domain as these technologies become pivotal in treating chronic diseases like cancer further validating mRNA as a versatile and powerful tool in precision medicine.
Approvals by the Regulatory Authorities Solidifying the Market Demand
In November 2023, CSL, a global biotechnology leader and Arcturus Therapeutics announced that ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older was approved by Japan's Ministry of Health, Labor and Welfare (MHLW). The approval of this vaccine recorded a significant milestone as the first sa-mRNA vaccine in the world. The approval by the MHLW supported the wider applications of the vaccine beyond COVID-19, owing to its efficacy and safety. The approval may also trigger regulatory authorities across the globe to approve similar mRNA treatments and vaccines to enable easy availability, boosting market growth. Underscoring the hidden potential of mRNA technology in developing medical treatments and public health, the market is poised to be propelled for an upward trajectory in the forecast period.
The market is witnessing continuous research and innovation in mRNA technology which is expected to discover new therapeutic opportunities. The research activities may find widespread applications beyond COVID-19, such as regenerative medicine, tissue engineering, and gene therapy.
Technological advancements are enabling the development of new and improved mRNA therapeutics in the market. The introduction of improved mRNA delivery systems, formulation techniques, and manufacturing processes are leading to enhanced efficacy, stability, and scalability of mRNA-based products.
The escalating demand for personalised medicine is contributing to market growth. Personalised medicine enables the development of targeted therapies with increased efficacy and reduced side effects, compared to conventional treatments.
The substantial efficacy and validation of mRNA vaccines have attracted significant investment and funding into companies and research organisations working on mRNA-based technologies. This influx of capital is fueling research and development activities, driving innovation in the mRNA market.
The EMR’s report titled “mRNA Vaccines and Therapeutics Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Breakup by Treatment Type
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Vaccines Dominate the Product Segment
The product segments include vaccines and drugs. Vaccines are further segmented into self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines. Self-amplifying mRNA-based vaccines stand out due to their potential for enhanced immunogenicity, longer-lasting immune responses, and scalability in manufacturing. Vaccines dominate the product segment as they play a critical role in preventing infectious diseases and supporting public health. With the global emphasis on immunization, vaccines represent a foundation of preventive medicine, offering cost-effective and scalable solutions to fight a wide range of pathogens and protect global population.
Market Segmentation Based on Application Areas
Under application segmentation, there is cancer, infectious disease, rare genetic disease, respiratory disease, and others. The mRNA technology provides a promising approach towards personalized cancer immunotherapy, with continuous research focusing on its efficacy, safety, and therapeutic benefits.
Based on the regional analysis, the market report covers North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with each region contributing to the overall dynamics of the market. North America leads the market due to robust research and development activities along with a favorable regulatory environment. Europe is following North America driven by the increasing investments in mRNA technology. Asia-Pacific is poised to witness significant growth with rising healthcare expenditure and expanding biotech sector.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, clinical trials analysis and strategic initiatives by the leading key players. The major companies in the market are as follows:
Based out of Cambridge, United Kingdom, AstraZeneca has a strong focus on the discovery, development, and commercialization of prescription medicines. The company is continuing to expand its mRNA technology through collaborations and develop effective solutions in several therapeutic areas.
Established in 1849, Pfizer Inc., is one of the leading healthcare companies boasting a strong research and development department. The company collaborated with BioNTech and prepared one of the very first mRNA-based vaccines for COVID-19, known as BNT162b2 or Comirnaty.
It is a biotechnology company based in California, USA. The company is focused on developing genomic medicines with the help of its several proprietary technology platforms in gene therapy, gene editing, cell therapy, and genome regulation.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies in the market include Moderna, Inc., Sanofi, Argos Therapeutics, GlaxoSmithKline plc., Gennova Biopharmaceuticals Limited, DAIICHI SANKYO COMPANY, LIMITED and Boehringer Ingelheim International GmbH.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Application |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share